Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 16Melanoma 8Lung Neoplasms 8Neoplasm Metastasis 6Colorectal Neoplasms 6Solid Tumours 5Neoplasms 5Breast Neoplasms 4Uveal Melanoma 3Thyroid Neoplasms 3Pancreatic Neoplasms 3Neurofibromatosis 1 3Colonic Neoplasms 3Thyroid Cancer, Papillary 2Carcinoma, Hepatocellular 2Biliary Tract Neoplasms 2Adult Solid Neoplasm 2Thyroid Diseases 1Thymoma 1Solid Tumors 1Small Cell Lung Carcinoma 1Sarcoma 1Renal Insufficiency 1Rectal Neoplasms 1Optic Nerve Glioma 1Non-small Cell Lung Cancer Metastatic 1Neurofibrosarcoma 1Neurofibroma, Plexiform 1Neuroblastoma 1Myelodysplastic-Myeloproliferative Diseases 1

Interventions

Fluorouracil 128Leucovorin 120Oxaliplatin 101Irinotecan 89Bevacizumab 55Cetuximab 44Capecitabine 40Folfox protocol 29Panitumumab 22Colonoscopy 17Chemotherapy, Adjuvant 16Floxuridine 15Early Intervention, Educational 15Erlotinib Hydrochloride 13Surveys and Questionnaires 11IFL protocol 11Counseling 11Celecoxib 11Immunohistochemistry 10Gemcitabine 10Psychiatric Rehabilitation 9Methods 8Magnetic Resonance Spectroscopy 8Gene Expression Profiling 8Exercise 8Dexamethasone 8sargramostim 7Sorafenib 7Radiotherapy 7Nivolumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Colonic Neoplasms × AZD 6244 × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT01287130 2019-12-17

AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
10 enrolled
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT01217450 2014-05-29

Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
33 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡